AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus

RegulatoryC-CAR168Positive

AI Analysis

Summary

AbelZeta Pharma announced that C-CAR168, a cell-based therapeutic product, has received EMA PRIME Designation for the treatment of lupus nephritis and systemic lupus erythematosus. PRIME designation accelerates the development and review process for therapies addressing unmet medical needs.

Outcome Details

EMA PRIME Designation received

Importance:7/10

Sentiment:

0.75

EMA PRIME Designationcell-based therapyautoimmune diseaselupus nephritissystemic lupus erythematosus

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on July 20, 2026 2:19 PM

Read Original